export interface DrugApproval {
  approvalMonth: string;
  approvalDate: string;
  ndaBlaNumber: string;
  applicationNo: string;
  applicationType: string;
  brandName: string;
  activeIngredient: string;
  sponsor: string;
  indicationFull: string;
  therapeuticArea: string;
  isOncology: boolean;
  isBiosimilar: boolean;
  isNovelDrug: boolean;
  isOrphanDrug: boolean;
  isCberProduct?: boolean; // CBER-regulated product (tissue, cellular/gene therapy) - not in Drugs@FDA
  approvalType: string;
  supplementCategory?: string; // Supplement Categories or Approval Type
  notes: string;
  fdaUrl?: string;
}

export const fdaApprovals: DrugApproval[] = [
  // ===== 2026ë…„ 1ì›” ìŠ¹ì¸ (ì˜¤ë¦„ì°¨ìˆœ) =====
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-06",
    ndaBlaNumber: "NDA 213026",
    applicationNo: "213026",
    applicationType: "NDA",
    brandName: "AMONDYS 45",
    activeIngredient: "casimersen",
    sponsor: "Sarepta Theraps Inc",
    indicationFull: "ë“€ì„¼ ê·¼ì´ì˜ì–‘ì¦ ì¹˜ë£Œ (ì—‘ì† 45 ìŠ¤í‚µí•‘ ì¹˜ë£Œì œ)",
    therapeuticArea: "ì‹ ê²½ê³¼ - ê·¼ì´ì˜ì–‘ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-16 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213026",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 208411",
    applicationNo: "208411",
    applicationType: "NDA",
    brandName: "NARCAN",
    activeIngredient: "naloxone hydrochloride",
    sponsor: "Emergent",
    indicationFull: "ì˜¤í”¼ì˜¤ì´ë“œ ê³¼ëŸ‰íˆ¬ì—¬ ì‘ê¸‰ì¹˜ë£Œìš© ë¹„ê°• ìŠ¤í”„ë ˆì´",
    therapeuticArea: "ì‘ê¸‰ì˜í•™ - í•´ë…ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-10 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 211616",
    applicationNo: "211616",
    applicationType: "NDA",
    brandName: "NEXLETOL",
    activeIngredient: "bempedoic acid",
    sponsor: "Esperion Theraps Inc",
    indicationFull: "ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ ë³´ì¡°ì¹˜ë£Œ (ìŠ¤íƒ€í‹´ ë³‘ìš© ë˜ëŠ” ë‹¨ë…)",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ê³ ì§€í˜ˆì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-26 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211616",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 211617",
    applicationNo: "211617",
    applicationType: "NDA",
    brandName: "NEXLIZET",
    activeIngredient: "bempedoic acid; ezetimibe",
    sponsor: "Esperion Theraps Inc",
    indicationFull: "ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ ë³´ì¡°ì¹˜ë£Œ (ë³µí•©ì œ)",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ê³ ì§€í˜ˆì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-31 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211617",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-12",
    ndaBlaNumber: "NDA 211241",
    applicationNo: "211241",
    applicationType: "NDA",
    brandName: "ZYCUBON",
    activeIngredient: "copper histidinate",
    sponsor: "Sentynl Theraps Inc",
    indicationFull: "ë©˜ì¼€ìŠ¤ë³‘ ì¹˜ë£Œë¥¼ ìœ„í•œ êµ¬ë¦¬ ë³´ì¶©ì œ",
    therapeuticArea: "ëŒ€ì‚¬ì§ˆí™˜ - í¬ê·€ëŒ€ì‚¬ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (Type 1 - New Molecular Entity)",
    notes: "ğŸ†• ìµœì´ˆìŠ¹ì¸. ì‹ ê·œ ë¶„ìë¬¼ì§ˆ. í¬ê·€ì˜ì•½í’ˆ",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211241",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-14",
    ndaBlaNumber: "NDA 021588",
    applicationNo: "021588",
    applicationType: "NDA",
    brandName: "GLEEVEC",
    activeIngredient: "imatinib mesylate",
    sponsor: "Novartis",
    indicationFull: "ë§Œì„±ê³¨ìˆ˜ì„±ë°±í˜ˆë³‘, ìœ„ì¥ê´€ê¸°ì§ˆì¢…ì–‘ ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë°±í˜ˆë³‘",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-65 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 214783",
    applicationNo: "214783",
    applicationType: "NDA",
    brandName: "REZUROCK",
    activeIngredient: "belumosudil mesylate",
    sponsor: "Kadmon Pharms LLC",
    indicationFull: "ë§Œì„± ì´ì‹í¸ëŒ€ìˆ™ì£¼ë³‘ ì¹˜ë£Œ",
    therapeuticArea: "ë©´ì—­í•™ - ì´ì‹í¸ëŒ€ìˆ™ì£¼ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-12 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214783",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 216774",
    applicationNo: "216774",
    applicationType: "NDA",
    brandName: "ALVAIZ",
    activeIngredient: "eltrombopag choline",
    sponsor: "Teva Pharms Inc",
    indicationFull: "ë§Œì„± ë©´ì—­ í˜ˆì†ŒíŒê°ì†Œì¦ ì¹˜ë£Œ",
    therapeuticArea: "í˜ˆì•¡ì¢…ì–‘ë‚´ê³¼ - í˜ˆì†ŒíŒê°ì†Œì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-6 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216774",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "NDA 021529",
    applicationNo: "021529",
    applicationType: "NDA",
    brandName: "NEXPLANON",
    activeIngredient: "etonogestrel",
    sponsor: "Organon",
    indicationFull: "í”¼í•˜ ì„í”Œë€íŠ¸í˜• í”¼ì„ì œ",
    therapeuticArea: "ì‚°ë¶€ì¸ê³¼ - í”¼ì„",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-27 - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ìœ íš¨ì„± ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021529",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "NDA 212849",
    applicationNo: "212849",
    applicationType: "NDA",
    brandName: "RYKINDO",
    activeIngredient: "risperidone",
    sponsor: "Shandong Luye",
    indicationFull: "ì¡°í˜„ë³‘ ì¹˜ë£Œ (ì„œë°©í˜• ì£¼ì‚¬ì œ)",
    therapeuticArea: "ì •ì‹ ê±´ê°•ì˜í•™ê³¼ - í•­ì •ì‹ ë³‘ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-3 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212849",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 022211",
    applicationNo: "022211",
    applicationType: "NDA",
    brandName: "ZIRGAN",
    activeIngredient: "ganciclovir",
    sponsor: "Bausch and Lomb",
    indicationFull: "ê¸‰ì„± í—¤ë¥´í˜ìŠ¤ ê°ë§‰ì—¼ ì¹˜ë£Œ (ì•ˆê³¼ìš© ê²”)",
    therapeuticArea: "ì•ˆê³¼ - í•­ë°”ì´ëŸ¬ìŠ¤ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-7 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022211",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "NDA 213535",
    applicationNo: "213535",
    applicationType: "NDA",
    brandName: "EVRYSDI",
    activeIngredient: "risdiplam",
    sponsor: "Genentech Inc",
    indicationFull: "ì²™ìˆ˜ì„± ê·¼ìœ„ì¶•ì¦(SMA) ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì²™ìˆ˜ì„±ê·¼ìœ„ì¶•ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-15 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213535",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "NDA 214377",
    applicationNo: "214377",
    applicationType: "NDA",
    brandName: "VERQUVO",
    activeIngredient: "vericiguat",
    sponsor: "MSD",
    indicationFull: "ì‹¬ë¶€ì „ ì¹˜ë£Œ (ì¦ìƒì„± ë§Œì„±ì‹¬ë¶€ì „)",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ì‹¬ë¶€ì „",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-5 - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ìœ íš¨ì„± ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214377",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-22",
    ndaBlaNumber: "NDA 216834",
    applicationNo: "216834",
    applicationType: "NDA",
    brandName: "ZILBRYSQ",
    activeIngredient: "zilucoplan sodium",
    sponsor: "UCB Inc",
    indicationFull: "ì „ì‹ ì„± ì¤‘ì¦ê·¼ë¬´ë ¥ì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì¤‘ì¦ê·¼ë¬´ë ¥ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-13 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216834",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "NDA 022348",
    applicationNo: "022348",
    applicationType: "NDA",
    brandName: "CALDOLOR",
    activeIngredient: "ibuprofen",
    sponsor: "Cumberland Pharms",
    indicationFull: "í†µì¦ ë° ë°œì—´ ì¹˜ë£Œ (ì •ë§¥ì£¼ì‚¬ìš©)",
    therapeuticArea: "í†µì¦ì˜í•™ - ì§„í†µì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-28 - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ìœ íš¨ì„± ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022348",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "NDA 211243",
    applicationNo: "211243",
    applicationType: "NDA",
    brandName: "SPRAVATO",
    activeIngredient: "esketamine hydrochloride",
    sponsor: "Janssen Pharms",
    indicationFull: "ì¹˜ë£Œì €í•­ì„± ìš°ìš¸ì¦ ë° ê¸‰ì„± ìì‚´ì‚¬ê³  ë™ë°˜ ì£¼ìš”ìš°ìš¸ì¥ì•  ì¹˜ë£Œ (ë¹„ê°• ìŠ¤í”„ë ˆì´)",
    therapeuticArea: "ì •ì‹ ê±´ê°•ì˜í•™ê³¼ - í•­ìš°ìš¸ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-27 - REMS",
    notes: "ë³€ê²½ìŠ¹ì¸. REMS ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "NDA 219209",
    applicationNo: "219209",
    applicationType: "NDA",
    brandName: "JOURNAVX",
    activeIngredient: "suzetrigine",
    sponsor: "Vertex Pharms Inc",
    indicationFull: "ì¤‘ë“±ë„~ì¤‘ì¦ ê¸‰ì„± í†µì¦ ì¹˜ë£Œ (ë¹„ì˜¤í”¼ì˜¤ì´ë“œ ì§„í†µì œ)",
    therapeuticArea: "í†µì¦ì˜í•™ - ì§„í†µì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-9 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. NaV1.8 ì–µì œì œ. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219209",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-26",
    ndaBlaNumber: "NDA 216395",
    applicationNo: "216395",
    applicationType: "NDA",
    brandName: "QUIOFIC",
    activeIngredient: "folic acid",
    sponsor: "CMP Dev LLC",
    indicationFull: "ì—½ì‚° ë³´ì¶©ì œ (ì‹ ê·œ ì œí˜•)",
    therapeuticArea: "ë‚´ê³¼ - ë¹„íƒ€ë¯¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (Type 3 - New Dosage Form)",
    notes: "ğŸ†• ìµœì´ˆìŠ¹ì¸. ìƒˆë¡œìš´ ì œí˜•",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216395",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 021024",
    applicationNo: "021024",
    applicationType: "NDA",
    brandName: "PRIFTIN",
    activeIngredient: "rifapentine",
    sponsor: "Sanofi Aventis US",
    indicationFull: "ê²°í•µ ì¹˜ë£Œ ë° ì˜ˆë°©",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ê²°í•µì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-22 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021024",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 022003",
    applicationNo: "022003",
    applicationType: "NDA",
    brandName: "NOXAFIL",
    activeIngredient: "posaconazole",
    sponsor: "Schering",
    indicationFull: "ì¹¨ìŠµì„± ì§„ê·  ê°ì—¼ ì˜ˆë°© ë° ì¹˜ë£Œ",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ì§„ê· ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-34 - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ìœ íš¨ì„± ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022003",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 022405",
    applicationNo: "022405",
    applicationType: "NDA",
    brandName: "CAPRELSA",
    activeIngredient: "vandetanib",
    sponsor: "Genzyme Corp",
    indicationFull: "ê°‘ìƒì„  ìˆ˜ì§ˆì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ê°‘ìƒì„ ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-26 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 209401",
    applicationNo: "209401",
    applicationType: "NDA",
    brandName: "VYXEOS",
    activeIngredient: "cytarabine; daunorubicin",
    sponsor: "Jazz Pharms Therap",
    indicationFull: "ê¸‰ì„± ê³¨ìˆ˜ì„± ë°±í˜ˆë³‘ ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë°±í˜ˆë³‘",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-18 - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ìœ íš¨ì„± ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209401",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 218010",
    applicationNo: "218010",
    applicationType: "NDA",
    brandName: "IDOSE TR",
    activeIngredient: "travoprost",
    sponsor: "Glaukos",
    indicationFull: "ë…¹ë‚´ì¥ ë° ê³ ì•ˆì••ì¦ ì¹˜ë£Œ (ì§€ì†í˜• ì•ˆë‚´ ì„í”Œë€íŠ¸)",
    therapeuticArea: "ì•ˆê³¼ - ë…¹ë‚´ì¥",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-4 - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ìœ íš¨ì„± ê´€ë ¨ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218010",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-28",
    ndaBlaNumber: "NDA 021266",
    applicationNo: "021266",
    applicationType: "NDA",
    brandName: "VFEND",
    activeIngredient: "voriconazole",
    sponsor: "Pf Prism Cv",
    indicationFull: "ì§„ê·  ê°ì—¼ ì¹˜ë£Œë¥¼ ìœ„í•œ í•­ì§„ê· ì œ (ì •ì œ)",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ì§„ê· ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-59 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021266",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-28",
    ndaBlaNumber: "NDA 021267",
    applicationNo: "021267",
    applicationType: "NDA",
    brandName: "VFEND",
    activeIngredient: "voriconazole",
    sponsor: "Pf Prism Cv",
    indicationFull: "ì§„ê·  ê°ì—¼ ì¹˜ë£Œë¥¼ ìœ„í•œ í•­ì§„ê· ì œ (ì£¼ì‚¬ì œ)",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ì§„ê· ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-69 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021267",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-28",
    ndaBlaNumber: "NDA 021630",
    applicationNo: "021630",
    applicationType: "NDA",
    brandName: "VFEND",
    activeIngredient: "voriconazole",
    sponsor: "Pf Prism Cv",
    indicationFull: "ì§„ê·  ê°ì—¼ ì¹˜ë£Œë¥¼ ìœ„í•œ í•­ì§„ê· ì œ (í˜„íƒìš©)",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ì§„ê· ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-49 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021630",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-28",
    ndaBlaNumber: "NDA 202971",
    applicationNo: "202971",
    applicationType: "NDA",
    brandName: "ABILIFY MAINTENA KIT",
    activeIngredient: "aripiprazole",
    sponsor: "Otsuka Pharm Co Ltd",
    indicationFull: "ì¡°í˜„ë³‘ ë° ì–‘ê·¹ì„± ì¥ì•  ìœ ì§€ ì¹˜ë£Œ (ê·¼ìœ¡ì£¼ì‚¬ìš© ì„œë°©í˜• í˜„íƒì•¡)",
    therapeuticArea: "ì •ì‹ ê±´ê°•ì˜í•™ê³¼ - í•­ì •ì‹ ë³‘ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL-20 - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. ë¼ë²¨ë§ ë³€ê²½",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202971",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-28",
    ndaBlaNumber: "NDA 220142",
    applicationNo: "220142",
    applicationType: "NDA",
    brandName: "YUVEZZI",
    activeIngredient: "carbachol and brimondine tartrate",
    sponsor: "Visus Therapeutics Inc.",
    indicationFull: "ì•ˆê³¼ìš© ìš©ì•¡ - ìƒˆë¡œìš´ ì œí˜•",
    therapeuticArea: "ì•ˆê³¼ - ì•ˆê³¼ìš©ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (Type 3 - New Dosage Form)",
    notes: "ğŸ†• ìµœì´ˆìŠ¹ì¸. ìƒˆë¡œìš´ ì œí˜• (New Dosage Form)",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220142",
  },
  // ===== 2025ë…„ 12ì›” ìŠ¹ì¸ (ì˜¤ë¦„ì°¨ìˆœ) =====
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-01",
    ndaBlaNumber: "BLA 761343",
    applicationNo: "761343",
    applicationType: "BLA",
    brandName: "SELARSDI",
    activeIngredient: "ustekinumab-aekn",
    sponsor: "Alvotech",
    indicationFull: "ê±´ì„ , ê±´ì„ ì„± ê´€ì ˆì—¼, í¬ë¡ ë³‘, ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ìê°€ë©´ì—­ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Stelara (ustekinumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761343",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-01",
    ndaBlaNumber: "BLA 761399",
    applicationNo: "761399",
    applicationType: "BLA",
    brandName: "OMLYCLO",
    activeIngredient: "omalizumab-igec",
    sponsor: "Celltrion",
    indicationFull: "ì¤‘ë“±ë„~ì¤‘ì¦ ì•Œë ˆë¥´ê¸° ì²œì‹ ë° ë§Œì„± íŠ¹ë°œì„± ë‘ë“œëŸ¬ê¸° ì¹˜ë£Œ",
    therapeuticArea: "ë©´ì—­í•™ - ì²œì‹",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Xolair (omalizumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761399",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-02",
    ndaBlaNumber: "NDA 216059",
    applicationNo: "216059",
    applicationType: "NDA",
    brandName: "JAYPIRCA",
    activeIngredient: "pirtobrutinib",
    sponsor: "Loxo Oncology",
    indicationFull: "ë§Œì„± ë¦¼í”„êµ¬ì„± ë°±í˜ˆë³‘/ì†Œë¦¼í”„êµ¬ì„± ë¦¼í”„ì¢… ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë°±í˜ˆë³‘",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. BTK Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216059",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-02",
    ndaBlaNumber: "BLA 761232",
    applicationNo: "761232",
    applicationType: "BLA",
    brandName: "TEVIMBRA",
    activeIngredient: "tislelizumab-jsgr",
    sponsor: "BeiGene",
    indicationFull: "ë¹„ì†Œì„¸í¬íì•” ë° ì‹ë„í¸í‰ì„¸í¬ì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - íì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. PD-1 Blocking Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-03",
    ndaBlaNumber: "BLA 125816",
    applicationNo: "125816",
    applicationType: "BLA",
    brandName: "AVANCE",
    activeIngredient: "acellular nerve allograft-arwx",
    sponsor: "Axogen",
    indicationFull: "ë§ì´ˆì‹ ê²½ ë³µêµ¬ë¥¼ ìœ„í•œ ë¬´ì„¸í¬ ì‹ ê²½ ë™ì¢…ì´ì‹",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì‹ ê²½ë³µêµ¬",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    isCberProduct: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ ë¬´ì„¸í¬ ì‹ ê²½ ë™ì¢…ì´ì‹",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/avance-nerve-graft",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-05",
    ndaBlaNumber: "BLA 761066",
    applicationNo: "761066",
    applicationType: "BLA",
    brandName: "ETICOVO",
    activeIngredient: "etanercept-ykro",
    sponsor: "Samsung Bioepis",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, ê±´ì„ ì„± ê´€ì ˆì—¼, ê°•ì§ì„± ì²™ì¶”ì—¼, íŒìƒ ê±´ì„  ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Enbrel (etanercept) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761066",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-05",
    ndaBlaNumber: "BLA 761100",
    applicationNo: "761100",
    applicationType: "BLA",
    brandName: "ONTRUZANT",
    activeIngredient: "trastuzumab-dttb",
    sponsor: "Samsung Bioepis",
    indicationFull: "HER2 ì–‘ì„± ìœ ë°©ì•” ë° ì „ì´ì„± ìœ„ì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ìœ ë°©ì•”",
    isOncology: true,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Herceptin (trastuzumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761100",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-05",
    // Note: BLA 125486 corresponds to GAZYVA. BREYANZI is under BLA 125714.
    ndaBlaNumber: "BLA 125714",
    applicationNo: "125714",
    applicationType: "BLA",
    brandName: "BREYANZI",
    activeIngredient: "lisocabtagene maraleucel",
    sponsor: "Bristol Myers Squibb",
    indicationFull: "ì´ì „ì— ìµœì†Œ 2íšŒ ì´ìƒì˜ ì „ì‹  ì¹˜ë£Œë¥¼ ë°›ì€ ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë³€ì—°ë¶€ ë¦¼í”„ì¢…(MZL) ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë¦¼í”„ì¢…",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    isCberProduct: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ë³€ê²½ìŠ¹ì¸ - ë³€ì—°ë¶€ ë¦¼í”„ì¢… ì ì‘ì¦ í™•ëŒ€. CAR-T ì„¸í¬ì¹˜ë£Œì œ",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-08",
    ndaBlaNumber: "BLA 761363",
    applicationNo: "761363",
    applicationType: "BLA",
    brandName: "WINREVAIR",
    activeIngredient: "sotatercept-csrk",
    sponsor: "Merck",
    indicationFull: "íë™ë§¥ ê³ í˜ˆì••(PAH) ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - íë™ë§¥ê³ í˜ˆì••",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Activin Signaling Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761363",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-09",
    ndaBlaNumber: "NDA 212819",
    applicationNo: "212819",
    applicationType: "NDA",
    brandName: "RECARBRIO",
    activeIngredient: "imipenem; cilastatin; relebactam",
    sponsor: "Merck",
    indicationFull: "ë³µí•©ì„± ë³µê°•ë‚´ê°ì—¼ ë° ìš”ë¡œê°ì—¼, íë ´ ì¹˜ë£Œ",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ê· ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Carbapenem/Beta-lactamase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212819",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-09",
    ndaBlaNumber: "BLA 761286",
    applicationNo: "761286",
    applicationType: "BLA",
    brandName: "RYSTIGGO",
    activeIngredient: "rozanolixizumab-noli",
    sponsor: "UCB",
    indicationFull: "ì „ì‹ ì„± ì¤‘ì¦ê·¼ë¬´ë ¥ì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì¤‘ì¦ê·¼ë¬´ë ¥ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. FcRn Blocking Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761286",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-09",
    ndaBlaNumber: "BLA 125846",
    applicationNo: "125846",
    applicationType: "BLA",
    brandName: "WASKYRA",
    activeIngredient: "etuvetidigene autotemcel",
    sponsor: "Fondazione Telethon ETS",
    indicationFull: "Wiskott-Aldrich ì¦í›„êµ°(WAS) ì†Œì•„ ë° ì„±ì¸ í™˜ìì˜ ìœ ì „ì ì¹˜ë£Œ",
    therapeuticArea: "ë©´ì—­í•™ - ìœ ì „ìì¹˜ë£Œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    isCberProduct: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ WAS ìœ ì „ì ì¹˜ë£Œ",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/waskyra",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-10",
    ndaBlaNumber: "BLA 103795",
    applicationNo: "103795",
    applicationType: "BLA",
    brandName: "ENBREL",
    activeIngredient: "etanercept",
    sponsor: "Immunex/Amgen",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, ê±´ì„ ì„± ê´€ì ˆì—¼, ê°•ì§ì„± ì²™ì¶”ì—¼, íŒìƒ ê±´ì„ , ì†Œì•„ íŠ¹ë°œì„± ê´€ì ˆì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. TNF-alpha Blocker",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103795",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-10",
    ndaBlaNumber: "BLA 125276",
    applicationNo: "125276",
    applicationType: "BLA",
    brandName: "ACTEMRA",
    activeIngredient: "tocilizumab",
    sponsor: "Genentech",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, ê±°ëŒ€ì„¸í¬ë™ë§¥ì—¼, ì†Œì•„ íŠ¹ë°œì„± ê´€ì ˆì—¼, ì‚¬ì´í† ì¹´ì¸ ë°©ì¶œ ì¦í›„êµ° ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. Interleukin-6 Receptor Antagonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "NDA 218230",
    applicationNo: "218230",
    applicationType: "NDA",
    brandName: "BLUJEP",
    activeIngredient: "gepotidacin mesylate",
    sponsor: "GlaxoSmithKline",
    indicationFull: "í•©ë³‘ì¦ì´ ì—†ëŠ” ìš”ë¡œê°ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - í•­ê· ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Triazaacenaphthylene Antibacterial",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218230",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "BLA 761142",
    applicationNo: "761142",
    applicationType: "BLA",
    brandName: "UPLIZNA",
    activeIngredient: "inebilizumab-cdon",
    sponsor: "Viela Bio",
    indicationFull: "ì‹œì‹ ê²½ì²™ìˆ˜ì—¼ ìŠ¤í™íŠ¸ëŸ¼ ì¥ì•  ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì‹œì‹ ê²½ì²™ìˆ˜ì—¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. CD19-directed Cytolytic Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761142",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "BLA 761145",
    applicationNo: "761145",
    applicationType: "BLA",
    brandName: "DARZALEX FASPRO",
    activeIngredient: "daratumumab and hyaluronidase-fihj",
    sponsor: "Janssen Biotech",
    indicationFull: "ê³ ìœ„í—˜ ë¬´ì¦ìƒ ë‹¤ë°œê³¨ìˆ˜ì¢… ì„±ì¸ í™˜ìì˜ ë‹¨ë…ìš”ë²• ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë‹¤ë°œê³¨ìˆ˜ì¢…",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ë³€ê²½ìŠ¹ì¸ - ë¬´ì¦ìƒ ë‹¤ë°œê³¨ìˆ˜ì¢… ì‹ ê·œ ì ì‘ì¦",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "NDA 219884",
    applicationNo: "219884",
    applicationType: "NDA",
    brandName: "DAYBUE STIX",
    activeIngredient: "trofinetide",
    sponsor: "Acadia Pharmaceuticals",
    indicationFull: "ë ˆíŠ¸ ì¦í›„êµ° ì„±ì¸ ë° ì†Œì•„ í™˜ì ì¹˜ë£Œë¥¼ ìœ„í•œ ìƒˆë¡œìš´ ì œí˜•",
    therapeuticArea: "ì‹ ê²½ê³¼ - ë ˆíŠ¸ì¦í›„êµ°",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "ìƒˆë¡œìš´ ì œí˜• (New Dosage Form) ìŠ¹ì¸ - ìŠ¤í‹± í¬ì¥",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219884",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "NDA 219776",
    applicationNo: "219776",
    applicationType: "NDA",
    brandName: "ORLADEYO",
    activeIngredient: "berotralstat dihydrochloride",
    sponsor: "BioCryst",
    indicationFull: "ìœ ì „ì„± í˜ˆê´€ë¶€ì¢… ì˜ˆë°©ì„ ìœ„í•œ ìƒˆë¡œìš´ ì œí˜•",
    therapeuticArea: "ë©´ì—­í•™ - í˜ˆê´€ë¶€ì¢…",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "ìƒˆë¡œìš´ ì œí˜• (New Dosage Form) ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219776",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 219304",
    applicationNo: "219304",
    applicationType: "NDA",
    brandName: "ROMVIMZA",
    activeIngredient: "vimseltinib",
    sponsor: "Deciphera Pharmaceuticals",
    indicationFull: "ê±°ëŒ€ê±´ë§‰ì„¸í¬ì¢… ì¹˜ë£Œ",
    therapeuticArea: "ì •í˜•ì™¸ê³¼ - ì¢…ì–‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. CSF1R Kinase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219304",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "BLA 761338",
    applicationNo: "761338",
    applicationType: "BLA",
    brandName: "STEQEYMA",
    activeIngredient: "ustekinumab-stba",
    sponsor: "Celltrion",
    indicationFull: "ê±´ì„ , ê±´ì„ ì„± ê´€ì ˆì—¼, í¬ë¡ ë³‘, ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ìê°€ë©´ì—­ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Stelara (ustekinumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761338",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "BLA 761148",
    applicationNo: "761148",
    applicationType: "BLA",
    brandName: "ROLVEDON",
    activeIngredient: "eflapegrastim-xnst",
    sponsor: "Spectrum Pharmaceuticals",
    indicationFull: "í™”í•™ìš”ë²• ìœ ë°œ í˜¸ì¤‘êµ¬ê°ì†Œì¦ ì˜ˆë°©",
    therapeuticArea: "í˜ˆì•¡ë‚´ê³¼ - í˜¸ì¤‘êµ¬ê°ì†Œì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Long-acting G-CSF",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761148",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "BLA 761180",
    applicationNo: "761180",
    applicationType: "BLA",
    brandName: "ADBRY",
    activeIngredient: "tralokinumab",
    sponsor: "LEO Pharma",
    indicationFull: "ì¤‘ë“±ë„~ì¤‘ì¦ ì•„í† í”¼ í”¼ë¶€ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "í”¼ë¶€ê³¼ - ì•„í† í”¼í”¼ë¶€ì—¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Interleukin-13 Antagonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761180",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 216793",
    applicationNo: "216793",
    applicationType: "NDA",
    brandName: "AKEEGA",
    activeIngredient: "niraparib and abiraterone acetate",
    sponsor: "Janssen Biotech",
    indicationFull: "BRCA2 ë³€ì´ ì „ì´ì„± ê±°ì„¸ë¯¼ê°ì„± ì „ë¦½ì„ ì•”(mCSPC) ì„±ì¸ í™˜ì ì¹˜ë£Œë¥¼ ìœ„í•œ í”„ë ˆë“œë‹ˆì† ë³‘ìš©ìš”ë²•",
    therapeuticArea: "í•­ì•”ì œ - ì „ë¦½ì„ ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ê±°ì„¸ë¯¼ê°ì„± ì „ë¦½ì„ ì•” ìµœì´ˆ PARP ì–µì œì œ",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 218571",
    applicationNo: "218571",
    applicationType: "NDA",
    brandName: "CARDAMYST",
    activeIngredient: "etripamil",
    sponsor: "Milestone Pharmaceuticals",
    indicationFull: "ì„±ì¸ ë°œì‘ì„± ìƒì‹¬ì‹¤ì„± ë¹ˆë§¥(PSVT) ì¹˜ë£Œë¥¼ ìœ„í•œ ë¹„ê°• ìŠ¤í”„ë ˆì´",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ë¶€ì •ë§¥",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ PSVT ë¹„ê°• ìŠ¤í”„ë ˆì´",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 219491",
    applicationNo: "219491",
    applicationType: "NDA",
    brandName: "NUZOLVENCE",
    activeIngredient: "zoliflodacin",
    sponsor: "Qpex Biopharma",
    indicationFull: "ì„±ì¸ ì„ì§ˆ ì¹˜ë£Œë¥¼ ìœ„í•œ ê²½êµ¬ìš© í•­ìƒì œ",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - ì„±ë§¤ê°œê°ì—¼ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ spiropyrimidinetrione ê³„ì—´ í•­ìƒì œ",
    fdaUrl: "https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat-gonorrhea",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "BLA 761427",
    applicationNo: "761427",
    applicationType: "BLA",
    brandName: "LEROCHOL",
    activeIngredient: "lerodalcibep-liga",
    sponsor: "LIB Therapeutics",
    indicationFull: "ì´í˜•ì ‘í•© ê°€ì¡±ì„± ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ ë˜ëŠ” ë™ë§¥ê²½í™”ì„± ì‹¬í˜ˆê´€ì§ˆí™˜ í™˜ìì˜ LDL-C ê°ì†Œ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ê³ ì½œë ˆìŠ¤í…Œë¡¤",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ PCSK9 ì–µì œ ìœµí•©ë‹¨ë°±ì§ˆ",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-medicine-lowering-cholesterol",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-16",
    ndaBlaNumber: "BLA 761369",
    applicationNo: "761369",
    applicationType: "BLA",
    brandName: "HYMPAVZI",
    activeIngredient: "marstacimab-hncq",
    sponsor: "Pfizer",
    indicationFull: "Aí˜• ë˜ëŠ” Bí˜• í˜ˆìš°ë³‘ ì„±ì¸ ë° ì†Œì•„ í™˜ìì˜ ì¶œí˜ˆ ì˜ˆë°©",
    therapeuticArea: "í˜ˆì•¡ë‚´ê³¼ - í˜ˆìš°ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Tissue Factor Pathway Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761369",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-16",
    ndaBlaNumber: "BLA 761458",
    applicationNo: "761458",
    applicationType: "BLA",
    brandName: "EXDENSUR",
    activeIngredient: "depemokimab-ulaa",
    sponsor: "GSK",
    indicationFull: "í˜¸ì‚°êµ¬ í‘œí˜„í˜• ì¤‘ì¦ ì²œì‹ ì„±ì¸ í™˜ì ì¹˜ë£Œë¥¼ ìœ„í•œ ì¥ê¸°ì‘ìš© IL-5 ê¸¸í•­ì œ",
    therapeuticArea: "í˜¸í¡ê¸°ë‚´ê³¼ - ì²œì‹",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ ì¥ê¸°ì‘ìš© IL-5 ê¸¸í•­ì œ",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-16",
    ndaBlaNumber: "NDA 210858",
    applicationNo: "210858",
    applicationType: "NDA",
    brandName: "VYBRIQUE",
    activeIngredient: "sildenafil citrate",
    sponsor: "IBSA",
    indicationFull: "ë°œê¸°ë¶€ì „ ì¹˜ë£Œë¥¼ ìœ„í•œ ìƒˆë¡œìš´ ì œí˜•",
    therapeuticArea: "ë¹„ë‡¨ê¸°ê³¼ - ë°œê¸°ë¶€ì „",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "ìƒˆë¡œìš´ ì œí˜• (New Dosage Form) ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210858",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 125360",
    applicationNo: "125360",
    applicationType: "BLA",
    brandName: "XEOMIN",
    activeIngredient: "incobotulinumtoxinA",
    sponsor: "Merz Pharmaceuticals",
    indicationFull: "ê²½ë¶€ ê·¼ê¸´ì¥ì´ìƒ, ìƒì§€ ê²½ì§, ë¯¸ê°„ ì£¼ë¦„, ì¹¨í˜ë¦¼ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ê·¼ê¸´ì¥ì´ìƒ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Acetylcholine Release Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125360",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 125486",
    applicationNo: "125486",
    applicationType: "BLA",
    brandName: "GAZYVA",
    activeIngredient: "obinutuzumab",
    sponsor: "Genentech",
    indicationFull: "ë§Œì„± ë¦¼í”„êµ¬ì„± ë°±í˜ˆë³‘ ë° ì—¬í¬ì„± ë¦¼í”„ì¢… ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë¦¼í”„ì¢…",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. CD20-directed Cytolytic Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "NDA 209115",
    applicationNo: "209115",
    applicationType: "NDA",
    brandName: "RUBRACA",
    activeIngredient: "rucaparib camsylate",
    sponsor: "Clovis Oncology",
    indicationFull: "BRCA ë³€ì´ ì „ì´ì„± ê±°ì„¸ì €í•­ì„± ì „ë¦½ì„ ì•”(mCRPC) ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ì „ë¦½ì„ ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. PARP Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761334",
    applicationNo: "761334",
    applicationType: "BLA",
    brandName: "ZYNYZ",
    activeIngredient: "retifanlimab-dlwr",
    sponsor: "Incyte",
    indicationFull: "ì „ì´ì„± ë˜ëŠ” ì¬ë°œì„± êµ­ì†Œ ì§„í–‰ì„± ë©”ë¥´ì¼ˆ ì„¸í¬ì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - í”¼ë¶€ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. PD-1 Blocking Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761334",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761139",
    applicationNo: "761139",
    applicationType: "BLA",
    brandName: "ENHERTU",
    activeIngredient: "fam-trastuzumab deruxtecan-nxki",
    sponsor: "Daiichi Sankyo/AstraZeneca",
    indicationFull: "HER2 ì–‘ì„± ì ˆì œë¶ˆê°€ëŠ¥ ë˜ëŠ” ì „ì´ì„± ìœ ë°©ì•” ì„±ì¸ í™˜ìì˜ 1ì°¨ ì¹˜ë£Œë¥¼ ìœ„í•œ pertuzumab ë³‘ìš©ìš”ë²•",
    therapeuticArea: "í•­ì•”ì œ - ìœ ë°©ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ë³€ê²½ìŠ¹ì¸ - pertuzumab ë³‘ìš© 1ì°¨ ì¹˜ë£Œ",
    fdaUrl: "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761118",
    applicationNo: "761118",
    applicationType: "BLA",
    brandName: "ABRILADA",
    activeIngredient: "adalimumab-afzb",
    sponsor: "Pfizer",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, ê±´ì„ ì„± ê´€ì ˆì—¼, ê°•ì§ì„± ì²™ì¶”ì—¼, í¬ë¡ ë³‘, ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼, íŒìƒ ê±´ì„  ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Humira (adalimumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761118",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761433",
    applicationNo: "761433",
    applicationType: "BLA",
    brandName: "RYBREVANT FASPRO",
    activeIngredient: "amivantamab and hyaluronidase-lpuj",
    sponsor: "Johnson & Johnson",
    indicationFull: "EGFR ë³€ì´ ë¹„ì†Œì„¸í¬íì•” ì„±ì¸ í™˜ìì˜ í”¼í•˜ì£¼ì‚¬ ì œí˜• ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - íì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - New Dosage Form",
    notes: "ë³€ê²½ìŠ¹ì¸ - í”¼í•˜ì£¼ì‚¬ ì œí˜• ì¶”ê°€",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection/",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-18",
    ndaBlaNumber: "BLA 761473",
    applicationNo: "761473",
    applicationType: "BLA",
    brandName: "NUFYMCO",
    activeIngredient: "ranibizumab-leyk",
    sponsor: "Formycon",
    indicationFull: "í™©ë°˜ë³€ì„±, í™©ë°˜ë¶€ì¢…, ë‹¹ë‡¨ë§ë§‰ë³‘ì¦, ê·¼ì‹œì„± ë§¥ë½ë§‰ì‹ ìƒí˜ˆê´€ ì¹˜ë£Œ",
    therapeuticArea: "ì•ˆê³¼",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "BLA - Biosimilar",
    notes: "Lucentis (ranibizumab) ìƒí˜¸êµí™˜ê°€ëŠ¥ ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.fda.gov/drugs/biosimilars/fda-approves-ranibizumab-leyk-interchangeable-biosimilar-lucentis",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 209115",
    applicationNo: "209115",
    applicationType: "NDA",
    brandName: "RUBRACA",
    activeIngredient: "rucaparib",
    sponsor: "Clovis Oncology",
    indicationFull: "BRCA ë³€ì´ ì „ì´ì„± ê±°ì„¸ì €í•­ì„± ì „ë¦½ì„ ì•”(mCRPC) ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ì „ë¦½ì„ ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ë³€ê²½ìŠ¹ì¸ - mCRPC ì ì‘ì¦ ì¶”ê°€ (ì‹ ì†ìŠ¹ì¸â†’ì •ê·œìŠ¹ì¸ ì „í™˜)",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "BLA 761457",
    applicationNo: "761457",
    applicationType: "BLA",
    brandName: "OZILTUS",
    activeIngredient: "denosumab-mobz",
    sponsor: "Amneal Pharmaceuticals",
    indicationFull: "ë‹¤ë°œê³¨ìˆ˜ì¢… ë˜ëŠ” ê³ í˜•ì•” ê³¨ì „ì´ í™˜ìì˜ ê³¨ê²© ê´€ë ¨ ì‚¬ê±´ ì˜ˆë°©, ê³¨ê±°ëŒ€ì„¸í¬ì¢… ì¹˜ë£Œ, ì•…ì„±ì¢…ì–‘ ê³ ì¹¼ìŠ˜í˜ˆì¦ ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ê³¨ì „ì´",
    isOncology: true,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "BLA - Biosimilar",
    notes: "Xgeva (denosumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-denosumab-mobz-biosimilar-xgeva",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 219083",
    applicationNo: "219083",
    applicationType: "NDA",
    brandName: "MYQORZO",
    activeIngredient: "aficamten",
    sponsor: "Cytokinetics",
    indicationFull: "ì¦ìƒì´ ìˆëŠ” íì‡„ì„± ë¹„ëŒ€ì„± ì‹¬ê·¼ë³‘ì¦ ì„±ì¸ í™˜ìì˜ ê¸°ëŠ¥ì  ëŠ¥ë ¥ ë° ì¦ìƒ ê°œì„ ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ì‹¬ê·¼ë³‘ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ ì‹¬ê·¼ ì–µì œì œ",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "BLA 761456",
    applicationNo: "761456",
    applicationType: "BLA",
    brandName: "BONCRESA",
    activeIngredient: "denosumab-mobz",
    sponsor: "Amneal Pharmaceuticals",
    indicationFull: "ê³¨ë‹¤ê³µì¦, ê³¨ëŸ‰ê°ì†Œ, ê³¨ì ˆìœ„í—˜ ì¦ê°€ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ê³¨ë‹¤ê³µì¦",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "BLA - Biosimilar",
    notes: "Prolia (denosumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.fda.gov/drugs/biosimilars/fda-approves-denosumab-mobz-biosimilar-prolia",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 220449",
    applicationNo: "220449",
    applicationType: "NDA",
    brandName: "JASCAYD",
    activeIngredient: "nerandomilast",
    sponsor: "Boehringer Ingelheim",
    indicationFull: "íŠ¹ë°œì„± íì„¬ìœ ì¦ ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "í˜¸í¡ê¸°ë‚´ê³¼ - íì„¬ìœ ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "ì‹ ê·œ ì ì‘ì¦ìœ¼ë¡œ í†µí•© NDA ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220449",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "BLA 022458",
    applicationNo: "022458",
    applicationType: "BLA",
    brandName: "ELELYSO",
    activeIngredient: "taliglucerase alfa",
    sponsor: "Pfizer",
    indicationFull: "ê³ ì…”ë³‘ íš¨ì†Œ ëŒ€ì²´ ìš”ë²•",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ëŒ€ì‚¬ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Glucocerebrosidase",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "NDA 209988",
    applicationNo: "209988",
    applicationType: "NDA",
    brandName: "FUROSCIX",
    activeIngredient: "furosemide",
    sponsor: "scPharmaceuticals",
    indicationFull: "ìš¸í˜ˆì„± ì‹¬ë¶€ì „ í™˜ìì˜ í”¼í•˜ì£¼ì‚¬ìš© ì´ë‡¨ì œ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ì‹¬ë¶€ì „",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í”¼í•˜ì£¼ì‚¬ìš© Loop Diuretic",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209988",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "NDA 213721",
    applicationNo: "213721",
    applicationType: "NDA",
    brandName: "GAVRETO",
    activeIngredient: "pralsetinib",
    sponsor: "Rigel Pharmaceuticals",
    indicationFull: "RET ìœµí•© ì–‘ì„± ë¹„ì†Œì„¸í¬íì•” ë° ê°‘ìƒì„ ì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - íì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. RET Kinase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "BLA 761263",
    applicationNo: "761263",
    applicationType: "BLA",
    brandName: "LUNSUMIO",
    activeIngredient: "mosunetuzumab-axgb",
    sponsor: "Genentech",
    indicationFull: "ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ì—¬í¬ì„± ë¦¼í”„ì¢… ì„±ì¸ í™˜ìì˜ í”¼í•˜ì£¼ì‚¬ ì œí˜• ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë¦¼í”„ì¢…",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - New Dosage Form",
    notes: "ë³€ê²½ìŠ¹ì¸ - í”¼í•˜ì£¼ì‚¬ ì œí˜• ì¶”ê°€",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mosunetuzumab-axgb-subcutaneous-relapsed-or-refractory-follicular-lymphoma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "NDA 218316",
    applicationNo: "218316",
    applicationType: "NDA",
    brandName: "WEGOVY",
    activeIngredient: "semaglutide",
    sponsor: "Novo Nordisk",
    indicationFull: "ë¹„ë§Œ ë˜ëŠ” ê³¼ì²´ì¤‘ ì„±ì¸ ë° ì²­ì†Œë…„ì˜ ì²´ì¤‘ ê´€ë¦¬ë¥¼ ìœ„í•œ ìƒˆë¡œìš´ ì œí˜•",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ë¹„ë§Œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "ìƒˆë¡œìš´ ì œí˜• (New Dosage Form) ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "NDA 217338",
    applicationNo: "217338",
    applicationType: "NDA",
    brandName: "MUCINEX 12HR COLD & FEVER",
    activeIngredient: "dextromethorphan; guaifenesin; naproxen sodium",
    sponsor: "RB Health",
    indicationFull: "ê°ê¸° ë° ë°œì—´ ì¦ìƒ ì™„í™”ë¥¼ ìœ„í•œ ë³µí•©ì œ",
    therapeuticArea: "í˜¸í¡ê¸°ë‚´ê³¼ - ê°ê¸°",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "Type 4 - New Combination",
    notes: "ìƒˆë¡œìš´ ë³µí•©ì œ (New Combination) ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217338",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-23",
    ndaBlaNumber: "NDA 216196",
    applicationNo: "216196",
    applicationType: "NDA",
    brandName: "AQVESME",
    activeIngredient: "mitapivat",
    sponsor: "Agios Pharmaceuticals",
    indicationFull: "ì•ŒíŒŒ-ì§€ì¤‘í•´ë¹ˆí˜ˆ ë˜ëŠ” ë² íƒ€-ì§€ì¤‘í•´ë¹ˆí˜ˆ ì„±ì¸ í™˜ìì˜ ë¹ˆí˜ˆ ì¹˜ë£Œ",
    therapeuticArea: "í˜ˆì•¡ë‚´ê³¼ - ì§€ì¤‘í•´ë¹ˆí˜ˆ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ë³€ê²½ìŠ¹ì¸ - ì§€ì¤‘í•´ë¹ˆí˜ˆ ì ì‘ì¦ ì¶”ê°€",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-anemia-thalassemia-inherited-blood-disorder",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-23",
    ndaBlaNumber: "BLA 761152",
    applicationNo: "761152",
    applicationType: "BLA",
    brandName: "YARTEMLEA",
    activeIngredient: "narsoplimab-wuug",
    sponsor: "Omeros Corporation",
    indicationFull: "ì¡°í˜ˆëª¨ì„¸í¬ì´ì‹ ê´€ë ¨ í˜ˆì „ì„±ë¯¸ì„¸í˜ˆê´€ë³‘ì¦ 2ì„¸ ì´ìƒ ì†Œì•„ ë° ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "í˜ˆì•¡ë‚´ê³¼ - TA-TMA",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ MASP-2 ì–µì œì œ, Breakthrough Therapy ë° Orphan Drug ì§€ì •",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-30",
    ndaBlaNumber: "NDA 220152",
    applicationNo: "220152",
    applicationType: "NDA",
    brandName: "NEREUS",
    activeIngredient: "tradipitant",
    sponsor: "Vanda Pharmaceuticals",
    indicationFull: "ì„±ì¸ ë©€ë¯¸ ì˜ˆë°©",
    therapeuticArea: "ì‹ ê²½ê³¼ - ë©€ë¯¸",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA ìµœì´ˆ ìŠ¹ì¸ NK-1 ìˆ˜ìš©ì²´ ê¸¸í•­ì œ (ë©€ë¯¸ ì ì‘ì¦)",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-tradipitant-prevention-motion-sickness-adults",
  },
  // ===== 2026ë…„ 1ì›” ìŠ¹ì¸ (ì˜¤ë¦„ì°¨ìˆœ) =====
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-06",
    ndaBlaNumber: "NDA 213026",
    applicationNo: "213026",
    applicationType: "NDA",
    brandName: "AMONDYS 45",
    activeIngredient: "casimersen",
    sponsor: "Sarepta Therapeutics",
    indicationFull: "ë“€ì„¼ ê·¼ì´ì˜ì–‘ì¦ í™˜ìì˜ ì—‘ì† 45 ìŠ¤í‚¤í•‘ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ê·¼ì´ì˜ì–‘ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213026",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-07",
    ndaBlaNumber: "BLA 761406",
    applicationNo: "761406",
    applicationType: "BLA",
    brandName: "YESINTEK",
    activeIngredient: "ustekinumab-ttwe",
    sponsor: "Biocon Biologics",
    indicationFull: "ê±´ì„ , ê±´ì„ ì„± ê´€ì ˆì—¼, í¬ë¡ ë³‘, ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ìê°€ë©´ì—­ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Interleukin-12 Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761406",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-08",
    ndaBlaNumber: "NDA 218171",
    applicationNo: "218171",
    applicationType: "NDA",
    brandName: "ENSACOVE",
    activeIngredient: "ensartinib",
    sponsor: "Xcovery",
    indicationFull: "ALK ì–‘ì„± ë¹„ì†Œì„¸í¬íì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - íì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218171",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 208411",
    applicationNo: "208411",
    applicationType: "NDA",
    brandName: "NARCAN",
    activeIngredient: "naloxone hydrochloride",
    sponsor: "Emergent BioSolutions",
    indicationFull: "ì˜¤í”¼ì˜¤ì´ë“œ ê³¼ëŸ‰ë³µìš© ì‘ê¸‰ì¹˜ë£Œ",
    therapeuticArea: "ì‘ê¸‰ì˜í•™ - ì˜¤í”¼ì˜¤ì´ë“œê³¼ëŸ‰",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Safety/Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 211616",
    applicationNo: "211616",
    applicationType: "NDA",
    brandName: "NEXLETOL",
    activeIngredient: "bempedoic acid",
    sponsor: "Esperion Therapeutics",
    indicationFull: "ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ê³ ì½œë ˆìŠ¤í…Œë¡¤",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ATP-Citrate Lyase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211616",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 211617",
    applicationNo: "211617",
    applicationType: "NDA",
    brandName: "NEXLIZET",
    activeIngredient: "bempedoic acid; ezetimibe",
    sponsor: "Esperion Therapeutics",
    indicationFull: "ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ ì¹˜ë£Œ ë³µí•©ì œ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ê³ ì½œë ˆìŠ¤í…Œë¡¤",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ATP-Citrate Lyase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211617",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-12",
    ndaBlaNumber: "BLA 020367",
    applicationNo: "020367",
    applicationType: "BLA",
    brandName: "CEREZYME",
    activeIngredient: "imiglucerase",
    sponsor: "Genzyme",
    indicationFull: "ê³ ì…”ë³‘ íš¨ì†Œ ëŒ€ì²´ ìš”ë²•",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ëŒ€ì‚¬ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020367",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-12",
    ndaBlaNumber: "NDA 211241",
    applicationNo: "211241",
    applicationType: "NDA",
    brandName: "ZYCUBO",
    activeIngredient: "copper histidinate",
    sponsor: "Sentynl Therapeutics",
    indicationFull: "Menkes disease ì†Œì•„ í™˜ìì˜ êµ¬ë¦¬ ë³´ì¶© ì¹˜ë£Œ",
    therapeuticArea: "ì†Œì•„ê³¼ - ëŒ€ì‚¬ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "ì‹ ê·œ ë¶„ì ì‹¤ì²´ (NME). í¬ê·€ì˜ì•½í’ˆ. Breakthrough Therapy ë° Rare Pediatric Disease ì§€ì •",
    fdaUrl: "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-menkes-disease",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-13",
    ndaBlaNumber: "NDA 018735",
    applicationNo: "018735",
    applicationType: "NDA",
    brandName: "ISOVUE 200",
    activeIngredient: "iopamidol",
    sponsor: "Bracco",
    indicationFull: "ë°©ì‚¬ì„  ì¡°ì˜ì œ",
    therapeuticArea: "ì˜ìƒì˜í•™ - ì¡°ì˜ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. X-Ray Contrast Activity",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018735",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-13",
    ndaBlaNumber: "NDA 020327",
    applicationNo: "020327",
    applicationType: "NDA",
    brandName: "ISOVUE 300",
    activeIngredient: "iopamidol",
    sponsor: "Bracco",
    indicationFull: "ë°©ì‚¬ì„  ì¡°ì˜ì œ",
    therapeuticArea: "ì˜ìƒì˜í•™ - ì¡°ì˜ì œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. X-Ray Contrast Activity",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020327",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-13",
    ndaBlaNumber: "BLA 761274",
    applicationNo: "761274",
    applicationType: "BLA",
    brandName: "YESAFILI",
    activeIngredient: "aflibercept-jbvf",
    sponsor: "Samsung Bioepis",
    indicationFull: "í™©ë°˜ë³€ì„±, í™©ë°˜ë¶€ì¢…, ë‹¹ë‡¨ë§ë§‰ë³‘ì¦, ê·¼ì‹œì„± ë§¥ë½ë§‰ì‹ ìƒí˜ˆê´€ ì¹˜ë£Œ",
    therapeuticArea: "ì•ˆê³¼ - í™©ë°˜ë³€ì„±",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "BLA - Biosimilar",
    notes: "Eylea (aflibercept) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761274",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-14",
    ndaBlaNumber: "NDA 021588",
    applicationNo: "021588",
    applicationType: "NDA",
    brandName: "GLEEVEC",
    activeIngredient: "imatinib mesylate",
    sponsor: "Novartis",
    indicationFull: "ë§Œì„±ê³¨ìˆ˜ì„±ë°±í˜ˆë³‘ ë° ìœ„ì¥ê´€ê¸°ì§ˆì¢…ì–‘ ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë°±í˜ˆë³‘",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-14",
    ndaBlaNumber: "BLA 761420",
    applicationNo: "761420",
    applicationType: "BLA",
    brandName: "AVTOZMA",
    activeIngredient: "tocilizumab-asgn",
    sponsor: "Celltrion",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, ê±°ëŒ€ì„¸í¬ë™ë§¥ì—¼, ì‚¬ì´í† ì¹´ì¸ ë°©ì¶œ ì¦í›„êµ° ë“± ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Interleukin 6 Receptor Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761420",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "BLA 761027",
    applicationNo: "761027",
    applicationType: "BLA",
    brandName: "FILKRI",
    activeIngredient: "filgrastim-laha",
    sponsor: "Accord BioPharma",
    indicationFull: "í™”í•™ìš”ë²• ìœ ë°œ í˜¸ì¤‘êµ¬ê°ì†Œì¦ ì¹˜ë£Œ",
    therapeuticArea: "í˜ˆì•¡ë‚´ê³¼ - í˜¸ì¤‘êµ¬ê°ì†Œì¦",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "BLA - Biosimilar",
    notes: "Neupogen (filgrastim) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761027",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "BLA 761379",
    applicationNo: "761379",
    applicationType: "BLA",
    brandName: "OTULFI",
    activeIngredient: "ustekinumab-aauz",
    sponsor: "Fresenius Kabi",
    indicationFull: "ê±´ì„ , ê±´ì„ ì„± ê´€ì ˆì—¼, í¬ë¡ ë³‘, ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ìê°€ë©´ì—­ì§ˆí™˜",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Interleukin-12 Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761379",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 021920",
    applicationNo: "021920",
    applicationType: "NDA",
    brandName: "NAPROXEN SODIUM",
    activeIngredient: "naproxen sodium",
    sponsor: "BionPharma",
    indicationFull: "ì†Œì—¼ ì§„í†µì œ",
    therapeuticArea: "ì •í˜•ì™¸ê³¼ - ì§„í†µ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021920",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 216774",
    applicationNo: "216774",
    applicationType: "NDA",
    brandName: "ALVAIZ",
    activeIngredient: "cetirizine hydrochloride; pseudoephedrine hydrochloride",
    sponsor: "Teva Pharmaceuticals",
    indicationFull: "ì•Œë ˆë¥´ê¸° ë¹„ì—¼ ì¦ìƒ ì™„í™”",
    therapeuticArea: "ì´ë¹„ì¸í›„ê³¼ - ì•Œë ˆë¥´ê¸°",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216774",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "BLA 761269",
    applicationNo: "761269",
    applicationType: "BLA",
    brandName: "LEQEMBI",
    activeIngredient: "lecanemab-irmb",
    sponsor: "Eisai",
    indicationFull: "ì´ˆê¸° ì•Œì¸ í•˜ì´ë¨¸ë³‘ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì•Œì¸ í•˜ì´ë¨¸",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Amyloid Beta-directed Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "NDA 021529",
    applicationNo: "021529",
    applicationType: "NDA",
    brandName: "NEXPLANON",
    activeIngredient: "etonogestrel",
    sponsor: "Organon",
    indicationFull: "ì¥ê¸° í”¼ì„ ì´ì‹ì œ",
    therapeuticArea: "ì‚°ë¶€ì¸ê³¼ - í”¼ì„",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021529",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "NDA 212849",
    applicationNo: "212849",
    applicationType: "NDA",
    brandName: "RYKINDO",
    activeIngredient: "risperidone",
    sponsor: "Shandong Luye",
    indicationFull: "ì¡°í˜„ë³‘ ë° ì–‘ê·¹ì„± ì¥ì•  ì¹˜ë£Œ ì„œë°©í˜• ì œì œ",
    therapeuticArea: "ì •ì‹ ê±´ê°•ì˜í•™ê³¼ - ì¡°í˜„ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212849",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-17",
    ndaBlaNumber: "NDA 019708",
    applicationNo: "019708",
    applicationType: "NDA",
    brandName: "POTASSIUM CHLORIDE IN SODIUM CHLORIDE",
    activeIngredient: "potassium chloride; sodium chloride",
    sponsor: "B. Braun",
    indicationFull: "ì „í•´ì§ˆ ë³´ì¶© ìˆ˜ì•¡",
    therapeuticArea: "ì‘ê¸‰ì˜í•™ - ìˆ˜ì•¡",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019708",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 022211",
    applicationNo: "022211",
    applicationType: "NDA",
    brandName: "ZIRGAN",
    activeIngredient: "ganciclovir",
    sponsor: "Bausch and Lomb",
    indicationFull: "ë‹¨ìˆœí¬ì§„ ê°ë§‰ì—¼ ì¹˜ë£Œ",
    therapeuticArea: "ì•ˆê³¼ - ê°ë§‰ì—¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. DNA Polymerase Inhibitors",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022211",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 215866",
    applicationNo: "215866",
    applicationType: "NDA",
    brandName: "MOUNJARO",
    activeIngredient: "tirzepatide",
    sponsor: "Eli Lilly",
    indicationFull: "ì œ2í˜• ë‹¹ë‡¨ë³‘ ì¹˜ë£Œ",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ë‹¹ë‡¨ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. GIP/GLP-1 Receptor Agonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 217806",
    applicationNo: "217806",
    applicationType: "NDA",
    brandName: "ZEPBOUND",
    activeIngredient: "tirzepatide",
    sponsor: "Eli Lilly",
    indicationFull: "ë¹„ë§Œ ë° ê³¼ì²´ì¤‘ í™˜ìì˜ ì²´ì¤‘ ê´€ë¦¬",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ë¹„ë§Œ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. GIP/GLP-1 Receptor Agonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "BLA 761498",
    applicationNo: "761498",
    applicationType: "BLA",
    brandName: "AVTOZMA SC",
    activeIngredient: "tocilizumab-anoh",
    sponsor: "Celltrion",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼, ê±°ëŒ€ì„¸í¬ë™ë§¥ì—¼, ì‚¬ì´í† ì¹´ì¸ ë°©ì¶œ ì¦í›„êµ° ë“± ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "BLA - Biosimilar",
    notes: "Actemra (tocilizumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761498",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-26",
    ndaBlaNumber: "NDA 216395",
    applicationNo: "216395",
    applicationType: "NDA",
    brandName: "QUIOFIC",
    activeIngredient: "folic acid",
    sponsor: "CMP Development",
    indicationFull: "ì—½ì‚° ë³´ì¶©ì„ ìœ„í•œ ìƒˆë¡œìš´ ì œí˜•",
    therapeuticArea: "ì˜ì–‘ë³´ì¶© - ë¹„íƒ€ë¯¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "ìƒˆë¡œìš´ ì œí˜• (New Dosage Form) ìŠ¹ì¸",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216395",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 214783",
    applicationNo: "214783",
    applicationType: "NDA",
    brandName: "REZUROCK",
    activeIngredient: "belumosudil mesylate",
    sponsor: "Kadmon Pharmaceuticals",
    indicationFull: "ë§Œì„± ì´ì‹í¸ëŒ€ìˆ™ì£¼ë³‘ ì¹˜ë£Œ",
    therapeuticArea: "ë©´ì—­í•™ - ì´ì‹í¸ëŒ€ìˆ™ì£¼ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ROCK2 Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214783",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "BLA 761196",
    applicationNo: "761196",
    applicationType: "BLA",
    brandName: "ZYNLONTA",
    activeIngredient: "loncastuximab tesirine-lpyl",
    sponsor: "ADC Therapeutics",
    indicationFull: "ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ê´‘ë²”ìœ„ Bì„¸í¬ ë¦¼í”„ì¢… ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë¦¼í”„ì¢…",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Antibody-drug Conjugate",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761196",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "BLA 761238",
    applicationNo: "761238",
    applicationType: "BLA",
    brandName: "BRIUMVI",
    activeIngredient: "ublituximab-xiiy",
    sponsor: "TG Therapeutics",
    indicationFull: "ì¬ë°œì„± ë‹¤ë°œì„± ê²½í™”ì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ë‹¤ë°œì„±ê²½í™”ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. CD20-directed Cytolytic Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761238",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "NDA 214377",
    applicationNo: "214377",
    applicationType: "NDA",
    brandName: "VERQUVO",
    activeIngredient: "vericiguat",
    sponsor: "Merck Sharp & Dohme",
    indicationFull: "ë§Œì„± ì‹¬ë¶€ì „ ì¹˜ë£Œ",
    therapeuticArea: "ì‹¬ì¥ë‚´ê³¼ - ì‹¬ë¶€ì „",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Soluble Guanylate Cyclase Stimulator",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214377",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "NDA 213535",
    applicationNo: "213535",
    applicationType: "NDA",
    brandName: "EVRYSDI",
    activeIngredient: "risdiplam",
    sponsor: "Genentech",
    indicationFull: "ì²™ìˆ˜ì„± ê·¼ìœ„ì¶•ì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ê·¼ìœ„ì¶•ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. SMN2 Splicing Modifier",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213535",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "BLA 761275",
    applicationNo: "761275",
    applicationType: "BLA",
    brandName: "TYENNE",
    activeIngredient: "tocilizumab-aazg",
    sponsor: "Fresenius Kabi",
    indicationFull: "ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼ ë° ê¸°íƒ€ ìê°€ë©´ì—­ì§ˆí™˜ ì¹˜ë£Œ",
    therapeuticArea: "ë¥˜ë§ˆí‹°ìŠ¤ - ê´€ì ˆì—¼",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. Interleukin 6 Receptor Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761275",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-22",
    ndaBlaNumber: "NDA 216834",
    applicationNo: "216834",
    applicationType: "NDA",
    brandName: "ZILBRYSQ",
    activeIngredient: "zilucoplan sodium",
    sponsor: "UCB",
    indicationFull: "ì „ì‹ ì„± ì¤‘ì¦ê·¼ë¬´ë ¥ì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - ì¤‘ì¦ê·¼ë¬´ë ¥ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Complement C5 Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216834",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "NDA 022348",
    applicationNo: "022348",
    applicationType: "NDA",
    brandName: "CALDOLOR",
    activeIngredient: "ibuprofen",
    sponsor: "Cumberland Pharmaceuticals",
    indicationFull: "ë°œì—´ ë° í†µì¦ ê´€ë¦¬ë¥¼ ìœ„í•œ ì •ë§¥ì£¼ì‚¬ì œ",
    therapeuticArea: "ì‘ê¸‰ì˜í•™ - ì§„í†µ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. ì •ë§¥ì£¼ì‚¬ìš© NSAIDs",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022348",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "BLA 022472",
    applicationNo: "022472",
    applicationType: "BLA",
    brandName: "AFREZZA",
    activeIngredient: "insulin recombinant human",
    sponsor: "MannKind",
    indicationFull: "ì œ1í˜•/ì œ2í˜• ë‹¹ë‡¨ë³‘ ì„±ì¸ í™˜ìì˜ í˜ˆë‹¹ ì¡°ì ˆì„ ìœ„í•œ í¡ì…í˜• ì¸ìŠë¦°",
    therapeuticArea: "ë‚´ë¶„ë¹„ë‚´ê³¼ - ë‹¹ë‡¨ë³‘",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "ë³€ê²½ìŠ¹ì¸. í¡ì…í˜• ì¸ìŠë¦°",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022472",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "NDA 211243",
    applicationNo: "211243",
    applicationType: "NDA",
    brandName: "SPRAVATO",
    activeIngredient: "esketamine hydrochloride",
    sponsor: "Janssen Pharmaceuticals",
    indicationFull: "ì¹˜ë£Œì €í•­ì„± ìš°ìš¸ì¦ ë° ìì‚´ìœ„í—˜ ì„±ì¸ í™˜ì ì¹˜ë£Œ",
    therapeuticArea: "ì •ì‹ ê±´ê°•ì˜í•™ê³¼ - ìš°ìš¸ì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Safety/REMS",
    notes: "ë³€ê²½ìŠ¹ì¸. NMDA Receptor Antagonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "NDA 219209",
    applicationNo: "219209",
    applicationType: "NDA",
    brandName: "JOURNAVX",
    activeIngredient: "suzetrigine",
    sponsor: "Vertex Pharmaceuticals",
    indicationFull: "ì¤‘ë“±ë„ ë‚´ì§€ ì¤‘ì¦ ê¸‰ì„± í†µì¦ ì¹˜ë£Œ",
    therapeuticArea: "ì‹ ê²½ê³¼ - í†µì¦",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. NaV1.8 Sodium Channel Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219209",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-23",
    ndaBlaNumber: "BLA 761340",
    applicationNo: "761340",
    applicationType: "BLA",
    brandName: "EPYSQLI",
    activeIngredient: "eculizumab-aagh",
    sponsor: "Samsung Bioepis",
    indicationFull: "ë°œì‘ì„± ì•¼ê°„í˜ˆìƒ‰ì†Œë‡¨ì¦, ë¹„ì •í˜• ìš©í˜ˆì„± ìš”ë… ì¦í›„êµ° ì¹˜ë£Œ",
    therapeuticArea: "í˜ˆì•¡ë‚´ê³¼ - PNH",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Soliris (eculizumab) ë°”ì´ì˜¤ì‹œë°€ëŸ¬",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761340",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 021024",
    applicationNo: "021024",
    applicationType: "NDA",
    brandName: "PRIFTIN",
    activeIngredient: "rifapentine",
    sponsor: "Sanofi Aventis",
    indicationFull: "ì ë³µê²°í•µ ë° í™œë™ì„± ê²°í•µ ì¹˜ë£Œ",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - ê²°í•µ",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Rifamycin-derivative Antibacterial",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021024",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 022003",
    applicationNo: "022003",
    applicationType: "NDA",
    brandName: "NOXAFIL",
    activeIngredient: "posaconazole",
    sponsor: "Schering",
    indicationFull: "ì¹¨ìŠµì„± ì•„ìŠ¤í˜ë¥´ê¸¸ë£¨ìŠ¤ì¦ ë° ì¹¸ë””ë‹¤ì¦ ì˜ˆë°© ë° ì¹˜ë£Œ",
    therapeuticArea: "ê°ì—¼ë‚´ê³¼ - ì§„ê· ê°ì—¼",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. Triazole Antifungal",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022003",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 022405",
    applicationNo: "022405",
    applicationType: "NDA",
    brandName: "CAPRELSA",
    activeIngredient: "vandetanib",
    sponsor: "Genzyme",
    indicationFull: "ì§„í–‰ì„± ìˆ˜ì§ˆì„± ê°‘ìƒì„ ì•” ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ê°‘ìƒì„ ì•”",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Labeling",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. VEGFR/EGFR/RET Kinase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 209401",
    applicationNo: "209401",
    applicationType: "NDA",
    brandName: "VYXEOS",
    activeIngredient: "cytarabine; daunorubicin",
    sponsor: "Jazz Pharmaceuticals",
    indicationFull: "ê³ ìœ„í—˜ ê¸‰ì„±ê³¨ìˆ˜ì„±ë°±í˜ˆë³‘ ì¹˜ë£Œ",
    therapeuticArea: "í•­ì•”ì œ - ë°±í˜ˆë³‘",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. í¬ê·€ì˜ì•½í’ˆ. ë¦¬í¬ì¢€ ë³µí•©ì œ",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209401",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "NDA 218010",
    applicationNo: "218010",
    applicationType: "NDA",
    brandName: "iDose TR",
    activeIngredient: "travoprost",
    sponsor: "Glaukos",
    indicationFull: "ë…¹ë‚´ì¥ ë° ê³ ì•ˆì••ì¦ ì¹˜ë£Œë¥¼ ìœ„í•œ ì§€ì†ë°©ì¶œí˜• ì•ˆë‚´ì‚½ì… ì¥ì¹˜",
    therapeuticArea: "ì•ˆê³¼ - ë…¹ë‚´ì¥",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy",
    notes: "ë³€ê²½ìŠ¹ì¸. Prostaglandin Analog Sustained-release Implant",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218010",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "BLA 761145",
    applicationNo: "761145",
    applicationType: "BLA",
    brandName: "DARZALEX FASPRO",
    activeIngredient: "daratumumab and hyaluronidase-fihj",
    sponsor: "Janssen Biotech",
    indicationFull: "ìê°€ ì¡°í˜ˆëª¨ì„¸í¬ì´ì‹ ë¶€ì ê²© ì‹ ê·œ ì§„ë‹¨ ë‹¤ë°œê³¨ìˆ˜ì¢… ì„±ì¸ í™˜ìì˜ bortezomib, lenalidomide, dexamethasone (VRd) ë³‘ìš©ìš”ë²•",
    therapeuticArea: "í•­ì•”ì œ - ë‹¤ë°œê³¨ìˆ˜ì¢…",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "ì •ê·œìŠ¹ì¸",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "ë³€ê²½ìŠ¹ì¸ - ì´ì‹ ë¶€ì ê²© NDMM VRd ë³‘ìš©ìš”ë²• ì ì‘ì¦ ì¶”ê°€",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly",
  },
];

export const summaryStats = {
  total: 57,
  oncology: 11,
  nonOncology: 46,
  biosimilar: 12,
  novelDrug: 11,
  novelOncology: 0,
  novelNonOncology: 11,
  orphanDrug: 18,
  orphanOncology: 7,
  orphanNonOncology: 11,
};

export const therapeuticAreaData = [
  { name: "ë‹¤ë°œê³¨ìˆ˜ì¢…", value: 2, category: "í•­ì•”ì œ" },
  { name: "ë¦¼í”„ì¢…", value: 2, category: "í•­ì•”ì œ" },
  { name: "ì „ë¦½ì„ ì•”", value: 2, category: "í•­ì•”ì œ" },
  { name: "íì•”", value: 2, category: "í•­ì•”ì œ" },
  { name: "ìœ ë°©ì•”", value: 1, category: "í•­ì•”ì œ" },
  { name: "ê³¨ì „ì´", value: 1, category: "í•­ì•”ì œ" },
  { name: "ë°±í˜ˆë³‘", value: 1, category: "í•­ì•”ì œ" },
  { name: "ëŒ€ì‚¬ì§ˆí™˜", value: 2, category: "ì†Œì•„ê³¼/ë‚´ë¶„ë¹„" },
  { name: "ë‹¹ë‡¨ë³‘", value: 2, category: "ë‚´ë¶„ë¹„ë‚´ê³¼" },
  { name: "ë¹„ë§Œ", value: 2, category: "ë‚´ë¶„ë¹„ë‚´ê³¼" },
  { name: "ê³ ì½œë ˆìŠ¤í…Œë¡¤", value: 3, category: "ì‹¬ì¥ë‚´ê³¼" },
  { name: "ê´€ì ˆì—¼/ìê°€ë©´ì—­", value: 5, category: "ë¥˜ë§ˆí‹°ìŠ¤" },
  { name: "íƒˆëª¨", value: 3, category: "í”¼ë¶€ê³¼" },
  { name: "ì¡°ì˜ì œ", value: 2, category: "ì˜ìƒì˜í•™" },
  { name: "ì‹ ê²½ê³¼", value: 5, category: "ì‹ ê²½ê³¼" },
  { name: "ì•ˆê³¼", value: 2, category: "ì•ˆê³¼" },
  { name: "í˜¸í¡ê¸°", value: 4, category: "í˜¸í¡ê¸°ë‚´ê³¼" },
  { name: "í˜ˆì•¡ë‚´ê³¼", value: 3, category: "í˜ˆì•¡ë‚´ê³¼" },
  { name: "ê¸°íƒ€", value: 13, category: "ê¸°íƒ€" },
];

export const approvalTypeData = [
  { name: "ì •ê·œìŠ¹ì¸", value: 57 },
  { name: "ì‹ ì†ìŠ¹ì¸", value: 0 },
];

export const drugCategoryData = [
  { name: "í•­ì•”ì œ", value: 11 },
  { name: "ë¹„í•­ì•”ì œ", value: 46 },
];

export const specialDesignations = [
  { name: "í¬ê·€ì˜ì•½í’ˆ", value: 18, percentage: 32 },
  { name: "ì‹ ì•½", value: 11, percentage: 19 },
  { name: "ë°”ì´ì˜¤ì‹œë°€ëŸ¬", value: 12, percentage: 21 },
];
